ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

Oramed Pharmaceuticals Inc. reported Q1 2026 results with $0 revenue and a net income of $38.31M, improving from a net loss of $(7.64) M in Q1 2025. Diluted EPS was $0.91, up from $(0.19) a year earlier. The company shifted to managing a medical technology portfolio, reduced R&D spending, and closed strategic transactions, including the Lifeward deal.

Oramed Pharmaceuticals Inc. reported first-quarter 2026 results with no product revenue and a swing to net income of $38.31M versus a net loss of $(7.64) M in the year-ago quarter; diluted EPS was $0.91 for Q1 2026 compared with $(0.19) in Q1 2025.

Financial Highlights

Revenue was $0 for Q1 2026, down from $2.0M in Q1 2025.
Net income was $38.31M for Q1 2026, compared with a net loss of $(7.64) M in Q1 2025 (improvement of $45.95M).
Diluted EPS was $0.91 for Q1 2026, versus $(0.19) in Q1 2025.

Business Highlights

Revenue shift: The company recorded no product revenue in Q1 2026 as license-related revenue recognition declined versus $2.0M a year earlier.
Portfolio strategy: Oramed transitioned to an active operator of a medical technology portfolio, acquiring controlling stakes and managing clinical and regulatory strategy for portfolio companies.
Clinical & R&D: R&D spending was reduced after prior Phase 3 terminations; the company plans to intensify the ORA-D-013-3 trial via OraTech and continues to manage POD™ trials.
Strategic transactions: Closed the Lifeward deal transferring POD™ IP and received equity and warrants, plus secured a revenue-share arrangement on ReWalk products.
Operational milestones: Invested in Alpha Tau and Lifeward, supported multiple Alpha Tau FDA trials and obtained Japan Shonin approval for Alpha DaRT.

Original SEC Filing: ORAMED PHARMACEUTICALS INC. [ ORMP ] - 10-Q - May. 19, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Financial Highlights

Revenue was $0 for Q1 2026, down from $2.0M in Q1 2025.
Net income was $38.31M for Q1 2026, compared with a net loss of $(7.64) M in Q1 2025 (improvement of $45.95M).
Diluted EPS was $0.91 for Q1 2026, versus $(0.19) in Q1 2025.

Business Highlights

Revenue shift: The company recorded no product revenue in Q1 2026 as license-related revenue recognition declined versus $2.0M a year earlier.
Portfolio strategy: Oramed transitioned to an active operator of a medical technology portfolio, acquiring controlling stakes and managing clinical and regulatory strategy for portfolio companies.
Clinical & R&D: R&D spending was reduced after prior Phase 3 terminations; the company plans to intensify the ORA-D-013-3 trial via OraTech and continues to manage POD™ trials.
Strategic transactions: Closed the Lifeward deal transferring POD™ IP and received equity and warrants, plus secured a revenue-share arrangement on ReWalk products.
Operational milestones: Invested in Alpha Tau and Lifeward, supported multiple Alpha Tau FDA trials and obtained Japan Shonin approval for Alpha DaRT.

Original SEC Filing: ORAMED PHARMACEUTICALS INC. [ ORMP ] - 10-Q - May. 19, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.